QUALIblood provides the industries, hospitals and universities with high-tech analytical services for biomarker investigations with an acute expertise in blood analysis. Each project is managed by a complementary scientific team evolving in a GCP/GLP and ISO17025 environment.
For each project and each development stage, QUALIblood designs customized solutions, defines analytical protocols, develops and validates specific analytical methods for biomarker evaluation.
QUALIblood offers a tailor-made accompaniment in biomarkers analyses by providing:
- Assistance in protocol definition to determine the testing strategy in agreement with the regulatory requirement and the scientific literature.
- Advice on (pre)analytical issues according to laboratory standards in the field.
- Identification of new biomarkers and development of innovative analytical methods.
QUALIblood also developed a new biomarker allowing to predict and prevent the risk of venous thromboembolism (VTE). In addition to its use in drug product development, this biomarker guides practicians in their prescription of hormonal treatments.
Up to now, QUALIblood has been mainly active in Belgium. Capitalizing on its experience, QUALIblood is eager to offer its services to customers from other countries.
